$42.35
0.34[0.81%]
At close: May 8
$42.35
0[0.00%]
PreMarket: 7:56PM EDT
Halozyme Therapeutics
(NASDAQ:HALO)Latest News for Halozyme Therapeutics Stock (NASDAQ:HALO)
Halozyme Therapeutics Stock (NASDAQ: HALO)
Categories: All
Wednesday, May 08, 2024
Tuesday, May 07, 2024
- Halozyme Therapeutics shares are trading higher following mixed Q1 results.Benzinga Newsdesk - 1 day ago
- Halozyme Reiterates FY24 Guidance: Sees Total Revenue $915M-$985M vs $951.47M Est., Adj. EPS $3.55-$3.90 vs $3.68 Est.Benzinga Newsdesk - 1 day ago
- Halozyme Therapeutics Q1 2024 Adj EPS $0.79 Beats $0.69 Estimate, Sales $195.879M Miss $199.777M EstimateBenzinga Newsdesk - 1 day ago
- Expert Ratings For Halozyme TherapeuticsBenzinga Insights - 1 day ago
- HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price TargetBenzinga Newsdesk - 1 day ago
Tuesday, April 30, 2024
Wednesday, April 17, 2024
Tuesday, April 16, 2024
Tuesday, April 09, 2024
Thursday, February 29, 2024
Wednesday, February 21, 2024
- Halozyme Therapeutics shares are trading higher after the company reported Q4 financial results and issued fY24 adjusted EPS guidance above estimates. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $48 to $50.Benzinga Newsdesk - Feb 21, 2024, 3:15PM
- JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price TargetBenzinga Newsdesk - Feb 21, 2024, 12:11PM
- Breaking Down Halozyme Therapeutics: 7 Analysts Share Their ViewsBenzinga Insights - Feb 21, 2024, 7:00AM
- HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $50Benzinga Newsdesk - Feb 21, 2024, 6:45AM
Tuesday, February 20, 2024
- Halozyme Therapeutics Sees FY24 Adj. EPS $3.55-$3.90 Vs $3.51 Est.; Revenue $915M-$985M Vs $961.088M Est.Benzinga Newsdesk - Feb 20, 2024, 4:40PM
- Halozyme Therapeutics: Q4 Earnings InsightsBenzinga Insights - Feb 20, 2024, 4:05PM
- Halozyme Therapeutics Q4 Adj EPS $0.82 Misses $0.83 Estimate, Sales $230.04M Miss $233.19M EstimateBenzinga Newsdesk - Feb 20, 2024, 4:03PM
- Earnings Scheduled For February 20, 2024Benzinga Insights - Feb 20, 2024, 6:52AM
Monday, February 19, 2024
Thursday, February 15, 2024
Monday, January 29, 2024
Friday, January 19, 2024
Thursday, January 18, 2024
- Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market ExpansionVandana Singh - Jan 18, 2024, 1:28PM
- Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 AnalystsBenzinga Insights - Jan 18, 2024, 12:00PM
- JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price TargetBenzinga Newsdesk - Jan 18, 2024, 11:39AM
- Halozyme Therapeutics shares are trading lower after HC Wainwright and Goldman Sachs lowered their respective price targets on the stock. The company announced that argenx received approval in Japan for VYVDURA injection co-formulated with ENHANZE.Benzinga Newsdesk - Jan 18, 2024, 11:28AM
- Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Lowers Price Target to $40Benzinga Newsdesk - Jan 18, 2024, 8:49AM
- Halozyme Announces argenx Received Approval In Japan For VYVDURA Co-Formulated With ENHANZE For Generalized Myasthenia GravisBenzinga Newsdesk - Jan 18, 2024, 8:32AM
- HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Lowers Price Target to $48Benzinga Newsdesk - Jan 18, 2024, 6:22AM
Wednesday, January 17, 2024
- Halozyme Therapeutics Sees FY25 EPS $4.10–$4.50, Revenue $1.04B–$1.115B; FY26 EPS $5.30–$5.80, Revenue $1.265B–$1.365B; FY27 EPS $6.70–$7.30, Revenue $1.515B–$1.64B; FY28 EPS $6.90–$7.50, Revenue $1.565B–$1.690BBenzinga Newsdesk - Jan 17, 2024, 1:06PM
- Halozyme Therapeutics Releases Investor Presentation: Sees FY23 EPS $2.77-$2.80 Vs $2.74 Est.; Revenue $827M-$832M Vs $835.69M Est.; FY24 EPS $3.55-$3.90 Vs $3.69 Est.; Revenue $915M-$985M Vs $1.1B Est.Benzinga Newsdesk - Jan 17, 2024, 12:56PM
Tuesday, January 16, 2024
- Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In EuropeVandana Singh - Jan 16, 2024, 11:38AM
- Roche Receives European Commission Approval Of Tecentriq SC With Halozyme's ENHANZE Representing The EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy For Multiple Cancer TypesBenzinga Newsdesk - Jan 16, 2024, 1:57AM
Tuesday, December 26, 2023
Thursday, November 16, 2023
Monday, November 06, 2023
- Halozyme Raises 2023 Adj. EPS Guidance To $2.70-$2.80 vs $2.65 Est.Benzinga Newsdesk - Nov 6, 2023, 4:44PM
- Halozyme Therapeutics Q3 2023 Adj EPS $0.75 Beats $0.73 Estimate, Sales $216.03M Miss $222.63M EstimateBenzinga Newsdesk - Nov 6, 2023, 4:31PM
- Earnings Scheduled For November 6, 2023Benzinga Insights - Nov 6, 2023, 8:24AM
- Acumen Pharmaceuticals, Inc. And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of ACU193 With ENHANZE TechnologyBenzinga Newsdesk - Nov 6, 2023, 7:31AM
Friday, November 03, 2023
Friday, October 20, 2023
Thursday, October 19, 2023
- Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest FindingsVandana Singh - Oct 19, 2023, 10:25AM
- Halozyme Therapeutics Highlights Bristol Myers Squibb Phase 3 CheckMate-67T Trial Results Of Subcutaneous Nivolumab With Halozyme's ENHANZE Drug Delivery Technology For Advanced Or Metastatic Clear Cell Renal Cell CarcinomaBill Haddad - Oct 19, 2023, 7:19AM
- Bristol Myers Squibb's Phase 3 Checkmate -67T Noninferiority Trial Of Subcutaneous Opdivo (Nivolumab) Compared To Intravenous Opdivo For Clear Cell Renal Cell Carcinoma Met Its Co-primary Pharmacokinetics Endpoints, Key Secondary EndpointBenzinga Newsdesk - Oct 19, 2023, 7:07AM
- HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $61Benzinga Newsdesk - Oct 19, 2023, 6:54AM